Loading stock data…
Tempus AI, Inc. (TEM)
$64.29-0.33 (-0.51%)
Market ClosedLast close Sep 8
Tempus AI, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tempus AI, Inc. in the Healthcare sector is trading at $64.29 with a market capitalization of $9.4B. Wall Street consensus targets $66.73 (15 analysts), implying a +3.8% move over the next 12 months. The stock is currently 38% below its 52-week high of $104.32, remaining 14.0% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $382.49M↑ | $348.12M↓ | $367.21M↑ | $334.21M↑ | $314.63M |
| Gross Profit | $246.50M↑ | $222.04M↓ | $237.71M↑ | $209.94M↑ | $195.04M |
| Operating Income | -$75.91M↑ | -$84.71M↓ | -$61.41M↓ | -$61.00M↑ | -$61.77M |
| Net Income | $5.64M↑ | -$125.92M↓ | -$54.17M↑ | -$79.98M↓ | -$42.84M |
Peer Comparison
JNJUNHPFE
Fundamentals
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.40B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.58
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-57.18%
Volume
Today's trading volume
5.18M
Recent News
The Cure for Cancer is Becoming an Investable Opportunity: Analyst Sees $600 Million for Tempus AI
Personalized cancer vaccines are creating a diagnostics investment opportunity beyond Moderna and Merck, with tumor sequencing at its center.
The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.
Tempus AI could capture a lucrative slice of Moderna and Merck’s personalized cancer therapy business, with Personalis at the center of the bet.
Tempus AI Got an $80 Target and 28% Upside Call. Is Wall Street Underestimating Its Healthcare Data Moat?
Tempus AI received a fresh vote of confidence on September 2 as Cantor Fitzgerald initiated coverage with an Overweight rating and an $80 price target. From the roughly $62.27 price cited with the call, that implied about 28% upside. The argument centers on a difficult-to-replicate combination: clinical data, diagnostics, software, and artificial intelligence operating inside […]
3 AI Stocks To Watch With Up To 45% Earnings Growth
With central banks lifting interest rates to tackle inflation, investors are hunting for themes that do not rely purely on cheap money to grow. Artificial intelligence in healthcare is one such story. It focuses on software and data rather than heavy assets. This article highlights three Transformative AI Healthcare Stocks from our screener that apply algorithms to diagnostics, treatment decisions, and hospital efficiency. The three stocks that follow are only a starting sample from this...
Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls
Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls